We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gastrointestinal PCR Assay Offers Rapid, Culture-Free Pathogen Identification

By LabMedica International staff writers
Posted on 17 Apr 2023
Print article
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)
Image: The LiquidArray Gastrointestinal assay detects up to 26 pathogens from stool samples in a two-well format (Photo courtesy of Bruker)

Gastroenteritis involves inflammation of the stomach and intestines' lining, typically characterized by diarrhea and/or vomiting. Gastrointestinal pathogens can cause life-threatening diseases, especially among children, immunosuppressed individuals, and the elderly. While most cases resolve within days, severe or persistent cases may necessitate hospitalization. Testing stool samples for potential causative agents—bacteria, viruses, parasites, and toxins—creates a substantial diagnostic burden in healthcare facilities. Now, a new syndromic panel for gastrointestinal infections that identifies 26 gastroenteritis-causing pathogens, including bacteria, viruses, parasites, and related toxins, aims to streamline routine procedures and enhance diagnostic efficiency.

Bruker Corporation’s (Billerica, MA, USA) new LiquidArray Gastrointestinal is a syndromic panel for gastrointestinal infections. The assay employs LiquidArray, a next-generation multiplexing technology, to detect up to 26 pathogens from stool samples using a two-well format that supports routine laboratory throughput needs. Introduced on the high-precision FluoroCycler XT thermocycler, LiquidArray merges innovative probe and thermocycling technologies with results-at-a-glance visualization for simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware XT-IVD generates easy-to-understand results, expediting clinical decisions.

LiquidArray Gastrointestinal is validated on the GenoXtract fleXT, a dependable, automated system for extracting nucleic acid from patient samples and setting up PCR plates. Barcode-supported robotic sorting minimizes manual intervention. Validated processing of LiquidArray Gastrointestinal on the GenoXtract fleXT offers a convenient walk-away solution tailored for dynamic laboratory environments. This equips high-throughput clinical labs with a fully integrated workflow from sample to result. The test is validated for use with stool samples, and a stool buffer developed for LiquidArray Gastrointestinal enables stabilization and storage of samples to be tested. The kit includes reagents for up to 48 reactions.

“The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run,” said Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division.

Related Links:
Bruker Corporation 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more